Clinical Trial Search

Primary: Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination — 0; 1; 1; 0 participants

Primary: Composite Rate of Peri-procedural (Within 30 Days of the Procedure) Death and Stroke, Plus Ipsilateral Stroke Between Day 31 and 1 Year (365 Days) — 4.4 percentage of…

Primary: Haemagglutination Inhibition (HI) Antibody Titers Against Each of the 4 Vaccine Influenza Strains — 716; 660; 740; 680 Subjects

Primary: Maximum Observed Plasma Concentration (Cmax) of Irinotecan — 1570; 1570 ng/mL

Primary: Change From Baseline in Direct LDL-C at Week 8 — -2.0; -1.5; -4.2; 0.2 Percent change — p=0.06

Primary: Change From Baseline in Average "Off" Time (Hours Per Day) at Week 12 — -1.0; -1.1; -0.8 hours per day — p=0.4933

Primary: Percentage of Participants With Occurrence of CDAD From Start of Study Treatment up to 30 Days Post-treatment Follow-up. — 28.6; 30.8 Percentage of participants — p=0.2778

Primary: Hepatic Fat — 4.7; 6.5 percent of liver fat

Primary: Percentage of Participants Who Achieved Clinical Response 50 (CR50; Crohn's Disease Activity Index [CDAI] Decrease ≥ 50 From Week 0) at Week 8 — 75 percentage of…

Primary: Minutes Per Week of Moderate-to-Vigorous Physical Activity (MPVA Min/wk) Assessed at 12 Weeks — 217.7; 203.2 MVPA minutes per week

Primary: Lowest Pain Level Postoperative — 1.66; 2.56 units on a scale

Primary: Change in Total Nasal Symptom Score From Baseline to Day 14. — -2.70; -4.05; -4.72; -4.05 units on a scale

Primary: AUC0-∞ — 10600; 12400; 13600 nmol*h/L

Primary: Percentage of Participants With Treatment-Related Grade 3-5 Adverse Events (AEs) During the Induction Period (Period 1 and 2) — 64.7; 51.4 Percentage of participants

Primary: Assessment of Toxicities to Define MTD of FOLFOX-Abraxane (A) for Newly Diagnosed, Advanced Pancreatic Cancer. — 1; 1; 2 participants